ClinicalTrials.gg
RecruitingNCT06616571Updated Sep 27, 2024

Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

A Phase 4 interventional study of QL0605(PEG-rhG-CSF) and QL0605(PEG-rhG-CSF) in Chemotherapy-Induced Febrile Neutropenia, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Febrile Neutropenia with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Febrile Neutropenia · China.

Planned enrollment
4th of 17
336 · median 150
Started
2024
with 1 other
Phase 4
2 of 20
1 open now
Registered
13th of 20
by date
Lead sponsor
2 of 20
Qilu Pharmaceutical Co., Ltd.

Among the 20 studies in Febrile Neutropenia with a site in China, this one is the 4th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 13th registered.

Febrile Neutropenia

147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.

Browse Febrile Neutropenia studies →

Open to participants now

8 of the 20 studies in Febrile Neutropenia with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Febrile Neutropenia studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Febrile Neutropenia with a site in China, or all of them as a file.
02

Study summary

The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.

Read the detailed description

Patients with stage invasive breast cancer who were scheduled to receive at least 2 cycles of adjuvant or neoadjuvant chemotherapy with TAC/TC/TCbH regimen were eligible for this multicenter, open-label, randomized trial. Patients were randomized (2:1) to receive QL0605 24 hours (24h group) or 48 hours (48h group) after the end of each cycle of chemotherapy. The primary endpoint was the incidence rate of FN for cycle 1. The secondary endpoints included the incidence rates of grade 3/4 neutropenia, chemotherapy dose reduction and chemotherapy delay due to neutropenia, antibiotic administration, the pain (bone, muscle, or joint), ect.

03

Conditions studied

  • Chemotherapy-Induced Febrile Neutropenia

Keywords

  • Febrile Neutropenia, Breast Cancer, Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged≥18 years;
  • The expected survival period is more than 3 months;
  • ≤ 2;
  • Invasive breast cancer diagnosed by histopathology;
  • Plan to receive TAC, TC or TCbH chemotherapy;
  • Subjects with good hematology, liver, lung and kidney function ;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Known to rhG-CSF or PEG-rhG-CSF;
  • Female patients during pregnancy or lactation;
  • The previous malignant tumors were not cured;
  • Received chemotherapy or radiotherapy within 4 weeks before screening;
  • Received PEG-rhG-CSF within 6 weeks before screening;
  • Suffering from uncontrollable infectious diseases within 2 weeks before screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    24h group

    Drug: QL0605(PEG-rhG-CSF)

  • Active comparator
    48h group

    Drug: QL0605(PEG-rhG-CSF)

Interventions

  • Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.

  • Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.

06

What researchers measure

Primary outcomes

  1. The incidence of febrile neutropenia for chemotherapy cycle 1.

    Febrile neutropenia is defined as single temperature: ≥38.3 °C orally(axillary 38.1°C) or ≥38.0 °C(axillary 37.8°C) over 2h; and neutropenia: \<500 neutrophils/mcL.

    Time frame: 21 days (Cycle 1 of chemotherapy treatment)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2025, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Sep 27, 2024
StartActual
Sep 19, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06616571
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Sep 19, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Sep 27, 2024

Study contacts

Mengli Zhu, Master
Contact
mengli.zhu@qilu-pharma.com
13256715221
Wangwang Zhi, Master
Contact
wangwang.zhi@qilu-pharma.com
17761716313

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion